Big Pharma Casts Immune Checkpoint Net Wide Across Tumor Types
Encouraged by data for a number of immune checkpoint molecules, Bristol, Merck and Roche are moving forward fast with development in many cancers, including melanoma, kidney cancer, lung cancer and hematologic malignancies. Trials in diseases with high unmet need could allow a faster route to approval for drugs in the anti-PD1 family.
You may also be interested in...
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.